Tonix Pharmaceuticals Price Target Announced at $18.00/Share by Canaccord Genuity

What happened

Canaccord Genuity started covering Tonix Pharmaceuticals with a Buy rating and set a price target of $18.00 per share, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A Buy rating means the broker expects the stock to rise, and the $18.00 target is its expected share price. This can draw investor attention to Tonix and may support demand for the stock.

Analyst inference

Analyst starting coverage often shapes how investors view a smaller drug company, because research from a known broker can raise awareness and invite more buying or selling of the shares.

Analyst inference

What to watch

1. Canaccord Genuity's stance is a Buy rating with an $18.00 per-share price target on Tonix Pharmaceuticals, as reported in the ratings actions. Confirmed
2. Watch whether other brokers begin covering Tonix, since more research coverage could change how easily investors can evaluate and trade the shares. Proposed
3. Track whether Tonix's actual business progress, such as drug development updates, lines up with the optimistic view implied by the Buy rating and target. Analyst inference

Evidence

• Original source link unavailable